Jazz Will Buy Rare-Disease Drugmaker Gentium for $1 Billion

Jazz Pharmaceuticals Plc, the maker of the narcolepsy treatment Xyrem, said it will buy Gentium SpA, a rare-disease drug developer, in a deal valued at $1 billion.

http://washpost.bloomberg.com/Story?docId=1376-MY2QG96TTDT201-5LDS6OJGQ8OT4VG8KQBQ69UPEU